AK Steel Holding Corporation (NYSE:AKS) on Nov. 4 reported a loss of $7.2 million in its third quarter. On a per-share basis, the company said it had a loss of 5 cents. Earnings, adjusted for costs related to mergers and acquisitions, came to 12 cents per share. The results surpassed Wall Street expectations. The average estimate of analysts was for earnings of 9 cents per share. The steel producer posted revenue of $1.59 billion in the period, which also topped Street forecasts. Analysts expected $1.48 billion, according to Zacks. AK Steel Holding Corporation (NYSE:AKS) belongs to Basic Materials sector. Its net profit margin is -1.70% and weekly performance is -15.81%. On last trading day company shares ended up $6.23. AK Steel Holding Corporation (NYSE:AKS) distance from 50-day simple moving average (SMA50) is -24.08%. Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (NASDAQ:ONCY) announced today that on October 29, 2014 it received a letter from the NASDAQ OMX Group ("Nasdaq") stating that the bid price of the Company's common stock for the 30 consecutive trading days from September 17, 2014 to October 28, 2014 had closed below the minimum $1.00 per share required for continued listing under Listing Rule 5550(a)(2). Oncolytics Biotech Inc. (NASDAQ:ONCY) shares decreased -12.35% in last trading session and ended the day at $0.71. ONCY return on assets is -85.20%. Oncolytics Biotech Inc. (NASDAQ:ONCY) quarterly performance is -47.01%. GenMark Diagnostics (NASDAQ:GNMK) SVP Jon Faiz Kayyem sold 6,000 shares of GenMark Diagnostics stock in a transaction that occurred on Friday, October 31st. The shares were sold at an average price of $11.01, for a total transaction of $66,060.00. Following the completion of the sale, the senior vice president now directly owns 108,947 shares of the company’s stock, valued at approximately $1,199,506. On 05 November, GenMark Diagnostics, Inc. (NASDAQ:GNMK) shares increased 2.55% and was closed at $11.27. GNMK EPS growth in last 5 year was 49.20%. GenMark Diagnostics, Inc. (NASDAQ:GNMK) year to date (YTD) performance is -15.20%. Saratoga Investment Corp. (NYSE:SAR) on Tuesday reported profit of $3.1 million in its fiscal second quarter. On a per-share basis, the New York-based company said it had net income of 58 cents. Earnings, adjusted for investment gains, came to 39 cents per share. The business development company posted revenue of $6.5 million in the period. Saratoga Investment Corp. (NYSE:SAR) ended the last trading day at $15.20. Company weekly volatility is calculated as 0.61% and price to cash ratio as 23.36. Saratoga Investment Corp. (NYSE:SAR) showed a weekly performance of 1.13%. MEDNAX Inc. (NYSE:MD) CEO Roger Md Medel sold 169,845 shares of MEDNAX stock on the open market in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $62.60, for a total transaction of $10,632,297.00. Following the completion of the transaction, the chief executive officer now directly owns 1,286,815 shares of the company’s stock, valued at approximately $80,554,619. MEDNAX, Inc. (NYSE:MD) shares increased 0.24% in last trading session and ended the day at $62.63. MD Gross Margin is 32.90% and its return on assets is 9.70%. MEDNAX, Inc. (NYSE:MD) quarterly performance is 12.83%.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
